Cytomegalovirus Retinitis, HIV Infections
Conditions
Keywords
Retinitis, Ganciclovir, Administration, Oral, Acquired Immunodeficiency Syndrome
Brief summary
To provide oral ganciclovir to patients who require maintenance for control of cytomegalovirus (CMV) retinitis, but who lack patent permanent central venous access for long-term administration of intravenous drugs.
Detailed description
Patients receive oral ganciclovir as maintenance. Patients enrolled at time of closure of enrollment will receive 2 months of study drug and undergo follow-up.
Interventions
DRUGGanciclovir
Sponsors
Hoffmann-La Roche
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must have: * AIDS. * Stable CMV retinitis. * Treatment with IV ganciclovir or IV foscarnet for at least 18 of the past 21 days. * No permanent central IV catheter at present. * Had a permanent central IV catheter removed two or more times within the past 6 months due to catheter infection or thrombosis. * Consent of guardian if less than legal age of consent.
Exclusion criteria
Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Require continuation of concomitant medications precluded by this protocol. Concurrent Medication: Excluded: * Intravitreal anti-CMV treatment. * Any other concomitant medications precluded by the protocol. Patients with the following prior condition are excluded: History of hypersensitivity to acyclovir or ganciclovir.
Countries
United States
Outcome results
None listed